main content start

Homepage

Latest Videos

Latest Videos

Brightcove Home Latest Listing

Breast Cancer

Breast Cancer

Brightcove Cards Listing

Prostate Cancer

Brightcove Cards Listing

Multiple Myeloma

Multiple Myeloma

Brightcove Cards Listing

Popular on MedEnrich

Popular in No name
  • Breast Cancer29m 30s

    SABCS Update 2022

    Summary of Key Abstracts from SABCS 2022
    recurrence score tailor-x destiny breast 03 adjuvant cdk4/6 inhibitor antibody drug conjugates
  • Breast Cancer8m 46s

    Expert Perspective - How I Treat Metastatic Her2 Positive Breast Cancer

    Anti-HER2 directed therapy remains the cornerstone of care for individuals with HER2-positive metastatic breast cancer (MBC).
    anti-her2 directed therapy her2-positive metastatic breast cancer expert perspective algorithm for management of her2 positive mbc
  • Breast Cancer8m 55s

    Understanding HER-2 Low Breast Cancer Entity & Treatment Strategy

    Tumors with a HER-2 immunohistochemistry (IHC) score of 1 + or 2 + and a negative molecular reflex test have been classified as HER2-low Breast Cancers.
    trastuzumab-deruxtecan (t-dxd) her2 low breast cancers
  • Breast Cancer3m 36s

    Tumor Infiltrating Lymphocytes as Predictive Biomarker in Breast Cancer

    Immune cells known as tumor-infiltrating lymphocytes (TILs) are thought to be a promising, affordable biomarker with prognostic and predictive potential.
    tumor-infiltrating lymphocytes (tils) promising biomarker
  • Breast Cancer36m 42s

    Clinical Challenges in Management of Hormone Receptor Positive -Her 2 Negative Advanced Breast Cancer (ABC)

    The landscape of HR+ve/HER2-negative metastatic breast cancer (MBC) has evolved significantly with the introduction of newer treatment options such as CDK4/6 inhibitors, PI3K inhibitors, and selective estrogen receptor down regulators.
    management of hr+/her2- breast cancer cdk4/6 inhibitors serds pi3k inhibitors biomarkers
  • Myelodysplastic Syndromes3m 14s

    Low Risk MDS - Key Practice Points

    Myelodysplastic Syndromes (MDS) or Myeloproliferative Neoplasms show considerable heterogeneity with respect to presence of anemia , cytopenia & molecular features.
    ipss -m low risk molecular features
  • Multiple Myeloma13m 11s

    Management of Infections in Multiple Myeloma

    Risk of infections in multiple myeloma has increased with the use of Novel treatments like Proteosome inhibitors, CD38 targeting MABs & BCMA targeted drugs.
    prophylaxis myeloma vaccination infections
  • Breast Cancer11m 28s

    ESR1 Mutation in Hormone Receptor Positive Advanced Breast Cancer

    ESR1 mutation leads to ligand independent activation of estrogen receptor. ESR1 mutations were first described in 1997 & their role remain underestimated as initial research was focused on primary tumor wherein these mutations were absent.
    aromatase inhibitor resistance hr +ve mbc esr1 mutation fulvestrant
  • Oncology13m 52s

    Guidelines for Treatment of Diffuse Gliomas

    Classification & treatment of Gliomas have evolved from erstwhile histopathology based to recent one incorporating molecular markers.
    glioma guidelines idh mutations
  • Myelodysplastic Syndromes4m 0s

    Selecting Right Patients for Early Initiation in HMAs in Low Risk MDS

    Selecting the right patients for early initiation of hypomethylating agents (HMAs) in low-risk MDS involves identifying those with progressive cytopenias, poor prognostic mutations, or high-risk features despite low-risk classification.
    hypomethylating agents (hmas) disease progression personalised treatment plans low risk mds
  • For Pharmacist

    For Pharmacist

    Brightcove Cards Listing

    Webinars

    Webinar Cards Listing

    MedBytes

    MedBytes

    Medbytes Cards Listing
    Hi, can I help?
    Chat SupportX
    Support Team
    Hello, how can I help you today?
    Please select one of the below options.

    Find Information

    Unable to Login or Register

    Want to share feedback